Cargando…
Prognostic Factors for the Therapeutic Performance of Cisplatin in Head and Neck Malignancies
INTRODUCTION: For squamous cell carcinoma of the head and neck (HNSCC), cisplatin is used as primary or adjuvant (radio)chemotherapy. In terms of dosage, two main regimens are used, weekly 40mg/m(2) or 3-weekly 100mg/m(2). For an optimal outcome, the highest possible cumulative total dose of cisplat...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096481/ https://www.ncbi.nlm.nih.gov/pubmed/35574347 http://dx.doi.org/10.3389/fonc.2022.778380 |